

# **Product** Data Sheet

### SNT-207707

Molecular Formula:

**Cat. No.:** HY-11029

CAS No.: 1064662-40-3

Molecular Weight: 550.18

Target: Melanocortin Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

 $C_{32}H_{44}CIN_5O$ 

**Storage:** 4°C, sealed storage, away from moisture

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO:  $\geq 250 \text{ mg/mL} (454.40 \text{ mM})$ 

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.8176 mL	9.0879 mL	18.1759 mL
	5 mM	0.3635 mL	1.8176 mL	3.6352 mL
	10 mM	0.1818 mL	0.9088 mL	1.8176 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility:  $\geq$  2.08 mg/mL (3.78 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility:  $\ge$  2.08 mg/mL (3.78 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.78 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	SNT-207707 is a selective, potent and orally active melanocortin MC-4 receptor antagonist with an IC $_{50}$ of 8 nM (binding) and 5 nM (function) on the MC-4 receptor.	
IC <sub>50</sub> & Target	IC50: 8 nM (binding MC-4), 5 nM (function MC-4) <sup>[1]</sup>	
In Vitro	SNT-207707 binds to the MC-4 receptor with an affinity of 8 nM and shows a more than 200-fold selectivity vs. MC-3 and MC-5. SNT207858 is a 22 nM MC-4 antagonist with a 170-fold selectivity vs. MC-3 and a 40-fold selectivity versus MC-5 <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

In Vivo

Single subcutaneous injection of 20 mg/kg of SNT-207707 distinctly increases food intake of the mice. Once daily oral administration of both compounds SNT207858 and SNT-207707 starting the day after tumor implantation significantly reduces the tumor induced weight loss<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **PROTOCOL**

Animal
Administration [1]

 $\mathsf{Mice}^{[1]}$ 

Twelve weeks old male CD-1 mice are dosed by gavage with either SNT-207707 or SNT207858 at 60 mg/kg (n=9 per compound). At 1, 3, and 6 hrs post-dose, 3 mice from each compound group are euthanized with CO<sup>2</sup>. Blood is collected by cardiac puncture, plasma is isolated immediately and then kept on dry ice until analysis<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Weyermann P, et al. Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS One. 2009;4(3):e4774.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA